Çınar 2020.
Study characteristics | ||
Methods |
|
|
Participants |
|
|
Interventions |
|
|
Outcomes |
|
|
Notes |
|
AE: adverse event; ALT: alanine aminotransferase; ARDS: acute respiratory distress syndrome; AST: aspartate transaminase; COI: conflict of interest; COPD: chronic obstructive pulmonary disease; CP: convalescent plasma; CPAP: continuous positive airway pressure; CPK: creatine phosphokinase; CRP: C‐reactive protein; CT: computed tomography; ECMO: extracorporeal membrane oxygenation; ELISA: enzyme‐linked immunosorbent assay; FiO2: fractional inspired oxygen; GI: gastrointestinal; HBV/HCV: hepatitis B/C; HLA: human leukocyte antigen; HNA: human neutrophil antigen; ICU: intensive care unit; IgA (B/G/M): immunoglobulin A (B/G/M); IL‐6: interleukin‐6; IQR: interquartile range; IRB: Institutional Review Board; IV: intravenous; IVIG: intravenous immunoglobulin; LDH: lactate dehydrogenase; MODS: multiple organ dysfunction syndrome; NR: not reported; OD: optical density; OSA: obstructive sleep apnoea; PaO2: arterial blood oxygen partial pressure; PCR: polymerase chain reaction; QoL: quality of life; RBD: receptor binding domain; RCT: randomised controlled trial; RNA: ribonucleic acid; RT‐PCR: reverse transcription polymerase chain reaction; SAE: serious adverse event; SARS: severe acute respiratory syndrome; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2; TACO: transfusion‐associated circulatory overload; TAD: transfusion‐associated dyspnoea; TRALI: transfusion‐related acute lung injury